Rating Change
JP Morgan reiterated its Overweight rating on CytomX Therapeutics, Inc. (NASDAQ:CTMX) on August 13, 2026.
reiterateNASDAQ:CTMX
JP Morgan Reiterates Overweight Rating on CytomX Therapeutics, Inc. (CTMX)
JP Morgan reiterated its Overweight rating on CytomX Therapeutics, Inc. (NASDAQ:CTMX) on August 13, 2026.
At publication ·
What changed
CytomX Therapeutics, Inc. (NASDAQ:CTMX) · reiterate
- Firm
- JP Morgan
- Rating
- Overweight to Overweight
- Price at event
- $3.33
- Market capitalization
- $686.8M
At a glance
Key takeaways
- JP Morgan reiterated an Overweight rating on CytomX Therapeutics (CTMX) on August 13, 2026, with the stock trading at $3.33 and a market capitalization of $686.8 million.
- Among the 10 most recent analyst ratings, all 10 are Buy or Overweight with zero Hold or Sell ratings, indicating strong consensus support for the stock.
Market Context
CytomX Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $3.33 with a market capitalization of $686.8M.
Analyst coverage from JP Morgan provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for CytomX Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for CytomX Therapeutics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 13, 2026 | JP Morgan | Overweight | N/A |
| Aug 10, 2026 | Guggenheim | Buy | N/A |
| May 11, 2026 | HC Wainwright & Co. | Buy | N/A |
| Mar 23, 2026 | Piper Sandler | Overweight | N/A |
| Mar 19, 2026 | Barclays | Overweight | N/A |
Related Tools: Analyst Ratings Dashboard | View CTMX Stock Page
Frequently Asked Questions
What does the Overweight rating mean for CTMX?
A rating of Overweight from JP Morgan reflects the analyst's outlook on CytomX Therapeutics, Inc. (NASDAQ:CTMX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the CTMX forecast page.
